Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Hematology
•
Pediatric Oncology
Do you routinely use thrombopoietin receptor agonists (like romiplostim) to address chemotherapy-induced thrombocytopenia in solid tumor pediatric oncology patients?
Related Questions
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney?
What workup do you complete for a teenage patient presenting with an incidentally discovered adrenal mass?
Do you use G-CSF for a patient with ALL admitted for febrile neutropenia with prolonged count recovery?
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
How would you proceed for a patient who has completed therapy for classic Hodgkin lymphoma with overall great disease response, but with new FDG avid lymph node on PET that is not amenable to biopsy?
How would you manage aplastic anemia refractory to multiple agents?
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
What is your approach to optimizing pre-operative hemoglobin in patients with sickle cell disease?
How would you counsel patients with personal or family histories of autoimmune disease on immune checkpoint inhibitor therapy for Hodgkin lymphoma?
